Table 2.
Verified continuous smoking abstinence and 7-day point prevalence of abstinence between two groups by intention-to-treat analysis (multiple imputation).
| Outcome | Intervention group |
Control group |
OR (95%CI) | AOR (95%CI)a | p-value |
|---|---|---|---|---|---|
| N = 1005 | N = 995 | ||||
| Primary outcome | |||||
| Verified abstinence | 120 (11.94%) | 28 (2.81%) | 4.68 (3.07–7.13) | 4.65 (3.09–7.23) | <0.0001 |
| Secondary outcomes | |||||
| Self-reported 7-day point prevalence of abstinence | |||||
| 1 week | 399 (39.70%) | 141 (14.17%) | 3.99 (3.21–4.96) | 4.08 (3.28–5.10) | <0.0001 |
| 4 weeks | 394 (39.20%) | 139 (13.97%) | 3.97 (3.19–4.94) | 4.09 (3.28–5.12) | <0.0001 |
| 8 weeks | 398 (39.60%) | 143 (14.37%) | 3.91 (3.15–4.86) | 4.05 (3.25–5.07) | <0.0001 |
| 12 weeks | 371 (36.92%) | 135 (13.57%) | 3.73 (2.99–4.66) | 3.84 (3.07–4.83) | <0.0001 |
| 16 weeks | 359 (35.72%) | 121 (12.16%) | 4.01 (3.19–5.05) | 4.11 (3.26–5.21) | <0.0001 |
| 20 weeks | 339 (33.73%) | 131 (13.17%) | 3.36 (2.68–4.21) | 3.43 (2.73–4.32) | <0.0001 |
| 26 weeks | 322 (32.04%) | 118 (11.86%) | 3.50 (2.77–4.42) | 3.54 (2.81–4.50) | <0.0001 |
| Self-reported continuous abstinence | |||||
| 4 weeks | 345 (34.33%) | 96 (9.65%) | 4.90 (3.83–6.28) | 5.01 (3.91–6.46) | <0.0001 |
| 8 weeks | 311 (30.95%) | 81 (8.14%) | 5.06 (3.89–6.59) | 5.18 (3.98–6.80) | <0.0001 |
| 12 weeks | 293 (29.15%) | 70 (7.04%) | 5.44 (4.12–7.19) | 5.59 (4.24–7.46) | <0.0001 |
| 16 weeks | 277 (27.56%) | 67 (6.73%) | 5.27 (3.97–7.00) | 5.38 (4.06–7.21) | <0.0001 |
| 20 weeks | 261 (25.97%) | 64 (6.43%) | 5.10 (3.82–6.81) | 5.18 (3.89–6.99) | <0.0001 |
| 26 weeks | 244 (24.28%) | 61 (6.13%) | 4.91 (3.65–6.60) | 4.95 (3.70–6.73) | <0.0001 |
OR: odds ratio; 95% CI: 95% confidence interval; AOR: adjusted odds ratio.
a
The analysis was adjusted for gender, age, education, urban-rural, regions, cigarettes smoked per day, FTCD score and previous quit attempts at baseline.